Search research articles
Contact Us
Filters
Showing results (191-200 of 209) with videos related to
Page
of 21
Sort By:
Clinical and Translational Medicine
|
June 23, 2025
Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study
Francesca Basso-Valentina, Vincenzo Canzonieri, Rossella De Cecio, et al.
Diagnostics (Basel, Switzerland)
|
September 23, 2022
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab
Marina Fabbi, Delfina Costa, Daniela Russo, et al.
British Journal of Haematology
|
July 12, 2022
Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study
Marco Picardi, Claudia Giordano, Novella Pugliese, et al.
The International Journal of Biological Markers
|
November 8, 2024
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial
Stefano Indraccolo, Simona Signoriello, Ilaria Piga, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 26, 2024
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial
Cristin Roma, Riziero Esposito Abate, Alessandra Sacco, et al.
International Journal of Molecular Sciences
|
June 24, 2022
Generation and Characterization of a Tumor Stromal Microenvironment and Analysis of Its Interplay with Breast Cancer Cells: An In Vitro Model to Study Breast Cancer-Associated Fibroblast Inactivation
Veronica Romano, Maria Rosaria Ruocco, Pietro Carotenuto, et al.
International Journal of Cancer
|
October 17, 2024
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study
Eliana Bignotti, Vittorio Simeon, Laura Ardighieri, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 11, 2023
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies
Federica Miglietta, Maria Vittoria Dieci, Tommaso Giarratano, et al.
Journal for Immunotherapy of Cancer
|
January 12, 2025
Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma
Daniela Esposito, Fabiana Napolitano, Daniela Claudia Maresca, et al.
Cell Death Discovery
|
March 28, 2026
CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells
Federica Auletta, Caterina Ieranò, Dario Guido Di Febbraro, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 209) with videos related to
Sort By:
Page
of 21
Clinical and Translational Medicine
|
June 23, 2025
Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study
Francesca Basso-Valentina, Vincenzo Canzonieri, Rossella De Cecio, et al.
Diagnostics (Basel, Switzerland)
|
September 23, 2022
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab
Marina Fabbi, Delfina Costa, Daniela Russo, et al.
British Journal of Haematology
|
July 12, 2022
Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study
Marco Picardi, Claudia Giordano, Novella Pugliese, et al.
The International Journal of Biological Markers
|
November 8, 2024
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial
Stefano Indraccolo, Simona Signoriello, Ilaria Piga, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 26, 2024
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial
Cristin Roma, Riziero Esposito Abate, Alessandra Sacco, et al.
International Journal of Molecular Sciences
|
June 24, 2022
Generation and Characterization of a Tumor Stromal Microenvironment and Analysis of Its Interplay with Breast Cancer Cells: An In Vitro Model to Study Breast Cancer-Associated Fibroblast Inactivation
Veronica Romano, Maria Rosaria Ruocco, Pietro Carotenuto, et al.
International Journal of Cancer
|
October 17, 2024
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study
Eliana Bignotti, Vittorio Simeon, Laura Ardighieri, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 11, 2023
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies
Federica Miglietta, Maria Vittoria Dieci, Tommaso Giarratano, et al.
Journal for Immunotherapy of Cancer
|
January 12, 2025
Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma
Daniela Esposito, Fabiana Napolitano, Daniela Claudia Maresca, et al.
Cell Death Discovery
|
March 28, 2026
CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells
Federica Auletta, Caterina Ieranò, Dario Guido Di Febbraro, et al.
Page
of 21